Last reviewed · How we verify

Thymanax — Competitive Intelligence Brief

Thymanax (AGOMELATINE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: agomelatine. Area: Neuroscience.

marketed agomelatine Melatonin receptor type 1A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Thymanax (AGOMELATINE) — Les Laboratoires Servier.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Thymanax TARGET AGOMELATINE Les Laboratoires Servier marketed agomelatine Melatonin receptor type 1A 2009-01-01
Rozerem RAMELTEON Takeda marketed Melatonin Receptor Agonist [EPC] Melatonin receptor type 1A 2005-01-01
Ovide MALATHION Taro marketed Cholinesterase Inhibitor [EPC] Melatonin receptor type 1A 1982-01-01
Rozerem Rozerem Northwestern University marketed Melatonin receptor type 1A, Melatonin receptor type 1B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (agomelatine class)

  1. Les Laboratoires Servier · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thymanax — Competitive Intelligence Brief. https://druglandscape.com/ci/agomelatine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: